MONTE ROSA THERAPEUTICS
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. Its rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond.
MONTE ROSA THERAPEUTICS
Industry:
Biotechnology Medical Therapeutics
Founded:
2018-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.monterosatx.com
Total Employee:
51+
Status:
Active
Contact:
917-363-0113
Email Addresses:
[email protected]
Total Funding:
223.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Google Tag Manager WordPress Wordpress Plugins Nginx Sitelinks Search Box
Similar Organizations
Aukera Therapeutics
Aukera Therapeutics is a biotech company that develops novel therapeutics for patients suffering from mTOR protein related diseases.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Advisors List
Current Employees Featured
Stock Details
Investors List
Amzak Health Investors
Amzak Health Investors investment in Series C - Monte Rosa Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Monte Rosa Therapeutics
Avoro Capital Advisors
Avoro Capital Advisors investment in Series C - Monte Rosa Therapeutics
Cambridge Asset Management
Cambridge Asset Management investment in Series C - Monte Rosa Therapeutics
RTW Investments LLC
RTW Investments LLC investment in Series C - Monte Rosa Therapeutics
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series C - Monte Rosa Therapeutics
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - Monte Rosa Therapeutics
GV
GV investment in Series C - Monte Rosa Therapeutics
Aisling Capital
Aisling Capital investment in Series C - Monte Rosa Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series C - Monte Rosa Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-02 | Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer |
Official Site Inspections
http://www.monterosatx.com Semrush global rank: 1.43 M Semrush visits lastest month: 19.57 K
- Host name: 191.103.223.35.bc.googleusercontent.com
- IP address: 35.223.103.191
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Monte Rosa Therapeutics"
Monte Rosa Therapeutics - Home
Nov 13, 2024ย ยท At Monte Rosa, weโve gone beyond boundaries with a team driven by innovation and a passion for medicine. Our experts in molecular glue degrader (MGD) chemistry, artificial โฆSee details»
Monte Rosa Therapeutics - About
At Monte Rosa, we are focused on the future. As we forge ahead, it's essential to glance back at the noteworthy milestones that shaped our journey. Markus brings over 20 years of experience in drug discovery and precision medicine to โฆSee details»
Investor Relations - Monte Rosa Therapeutics
Monte Rosa Therapeutics is a clinical stage biotechnology company developing novel molecular glue degrader (MGD) medicines for patients living with serious diseases such as oncology, autoimmune and inflammatory diseases.See details»
Monte Rosa Therapeutics - Pipeline
Monte Rosa Therapeutics Inc. is committed to developing therapies using our proprietary protein degradation platform, and we are focused on conducting the clinical trials needed to obtain โฆSee details»
Monte Rosa Therapeutics - Crunchbase Company โฆ
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. View contacts for Monte Rosa Therapeutics to access new leads and connect with decision โฆSee details»
Release Details - Monte Rosa Therapeutics
BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader โฆSee details»
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial โฆ
BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader โฆSee details»
Monte Rosa Therapeutics - LinkedIn
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of...See details»
Monte Rosa Therapeutics - Contact
Pioneering Therapies for Cancer and Beyond โ Our drug discovery platform is tailored to promote specific protein ubiquitination and subsequent proteasomal degradation of disease-causing, โฆSee details»
Monte Rosa Therapeutics Announces Leadership Team Promotions
May 30, 2024ย ยท Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious โฆSee details»
Monte Rosa Therapeutics to Present at the 40th Annual J.P.
Jan 4, 2022ย ยท Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader medicines. These medicines are designed to employ the bodyโs โฆSee details»
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year โฆ
BOSTON, March 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, โฆSee details»
iCIMS Careers Portal - careers-monterosatx.icims.com
Highly analytical mind, attention to detail and organization skills are critical. Experience with Biacore 8K+ and S200 is preferred.See details»
Monte Rosa Therapeutics Provides Development Progress
Jun 27, 2024ย ยท Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious โฆSee details»
Monte Rosa Therapeutics AG โ Swiss Biotech
Discover if your new anti-cancer drug will work! Our validated platform uses intact patients tumors, maintains their complexity and cellular component, and overcomes organoids. This allows to โฆSee details»
News - Monte Rosa Therapeutics
Oct 23, 2024ย ยท Pioneering Therapies for Cancer and Beyond โ Our drug discovery platform is tailored to promote specific protein ubiquitination and subsequent proteasomal degradation of โฆSee details»
Monte Rosa Therapeutics Reports Fourth Quarter and Full Year โฆ
BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD) โฆSee details»
GLUE Stock Price Quote | Morningstar
6 days agoย ยท Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage โฆSee details»
Monte Rosa Therapeutics - Science
Using geometric deep learning to identify targets, protein surfaces to match targets to ligases, and virtual screening to design MGDs, our integrated data moat and AI algorithms guide our drug โฆSee details»
monterosatx/gloop-mining: Code used in paper for G-loop โฆ
GitHub - monterosatx/gloop-mining: Code used in paper for G-loop mining. This repository contains the source code, data, and scripts related to the research on ฮฒ-hairpin G-loop motifs โฆSee details»